This article has been updated from a previous version to include DermTech's share price in Friday afternoon trading on the Nasdaq.
NEW YORK ─ Skin cancer diagnostic company DermTech this week announced that it has inked a contract that makes its Pigmented Lesion Assay available to approximately 6 million Blue Cross Blue Shield of Texas (BCBSTX) members.